Cosciens Biopharma INC F-1 registration statements
The S-1’s counterpart for foreign private issuers registering shares for sale in the United States.
NASDAQ
Aeterna Zentaris is issuing new warrants and common shares to facilitate the acquisition of Ceapro Inc., aiming to create a combined entity with a diversified product pipeline and stronger financial position.
NASDAQ
Aeterna Zentaris is pursuing the acquisition of Ceapro Inc. through a plan of arrangement involving the issuance of common shares and new warrants to existing shareholders and warrant holders.
NASDAQ
Aeterna Zentaris outlines the terms of warrant issuance as part of its acquisition of Ceapro Inc., detailing exercise conditions, price adjustments, and warrantholder rights.